Regeneron Pharmaceuticals (REGN) Other Operating Expenses (2009 - 2026)
Regeneron Pharmaceuticals' quarterly Other Operating Expenses came in at $771.3 million in Q1 2026, up 7613.0% quarter-over-quarter from $10.0 million in Q3 2025.
Regeneron Pharmaceuticals has reported Other Operating Expenses for 18 years, with the latest figure at $771.3 million in Q1 2026.
- For the quarter ending Q1 2026, Other Operating Expenses changed N/A year-over-year to $771.3 million; the trailing twelve-month figure through Mar 2026 stood at $781.3 million (up 2150.66% YoY), and the FY2025 full-year result was $10.0 million, up 118.73% from the prior year.
- Other Operating Expenses for Q1 2026 stood at $771.3 million, up from $10.0 million in the prior quarter.
- The five-year high for Other Operating Expenses was $771.3 million in Q1 2026, with the low at -$15.5 million in Q4 2024.
- Average Other Operating Expenses over 5 years is $58.6 million, with a median of $550000.0 recorded in 2023.
- Year-over-year, Other Operating Expenses tumbled 3200.0% in 2024 and soared 225.0% in 2025.
- Tracing REGN's Other Operating Expenses over 5 years: stood at $6.6 million in 2022, then sank by 92.42% to $500000.0 in 2023, then plunged by 3200.0% to -$15.5 million in 2024, then jumped by 164.52% to $10.0 million in 2025, then surged by 7613.0% to $771.3 million in 2026.
- The last three Other Operating Expenses figures came in at $771.3 million (Q1 2026), $10.0 million (Q3 2025), and -$15.5 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 771.30 Mn |
| Sep 30, 2025 | 10.00 Mn |
| Dec 31, 2024 | -15.50 Mn |
| Sep 30, 2024 | -8.00 Mn |
| Jun 30, 2024 | -14.60 Mn |
| Mar 31, 2024 | -15.30 Mn |
| Dec 31, 2023 | 500,000.00 |
| Sep 30, 2023 | 500,000.00 |
| Jun 30, 2023 | 600,000.00 |
| Mar 31, 2023 | 500,000.00 |
| Dec 31, 2022 | 6.60 Mn |
| Sep 30, 2022 | 45.70 Mn |
| Jun 30, 2022 | 17.40 Mn |
| Mar 31, 2022 | 20.20 Mn |
| Dec 31, 2021 | 15.80 Mn |
| Sep 30, 2021 | -42.00 Mn |
| Jun 30, 2021 | 31.30 Mn |
| Mar 31, 2021 | 40.50 Mn |
| Dec 31, 2020 | 145.20 Mn |
| Sep 30, 2020 | 44.60 Mn |
| Jun 30, 2020 | 50.20 Mn |
| Mar 31, 2020 | 40.40 Mn |
| Dec 31, 2019 | 38.10 Mn |
| Sep 30, 2019 | 50.70 Mn |
| Jun 30, 2019 | 63.70 Mn |
| Mar 31, 2019 | 56.70 Mn |
| Dec 31, 2018 | 1.26 Bn |
| Sep 30, 2018 | 110.40 Mn |
| Jun 30, 2018 | 91.70 Mn |
| Mar 31, 2018 | 114.90 Mn |
| Dec 31, 2017 | 105.78 Mn |
| Sep 30, 2017 | 104.23 Mn |
| Jun 30, 2017 | 102.92 Mn |
| Mar 31, 2017 | 84.17 Mn |
| Dec 31, 2016 | 74.69 Mn |
| Sep 30, 2016 | 44.23 Mn |
| Jun 30, 2016 | 69.03 Mn |
| Mar 31, 2016 | 111.75 Mn |
| Dec 31, 2015 | 110.83 Mn |
| Sep 30, 2015 | 109.08 Mn |
| Jun 30, 2015 | 88.84 Mn |
| Mar 31, 2015 | 83.96 Mn |
| Dec 31, 2014 | 203.22 Mn |
| Sep 30, 2014 | 55.59 Mn |
| Jun 30, 2014 | 46.38 Mn |
| Mar 31, 2014 | 43.57 Mn |
| Dec 31, 2013 | 48.11 Mn |
| Sep 30, 2013 | 38.57 Mn |
| Jun 30, 2013 | 39.61 Mn |
| Mar 31, 2013 | 29.06 Mn |
| Dec 31, 2012 | 30.17 Mn |
| Sep 30, 2012 | 20.15 Mn |
| Jun 30, 2012 | 21.84 Mn |
| Mar 31, 2012 | 12.30 Mn |
| Dec 31, 2011 | 2.99 Mn |
| Sep 30, 2011 | 450,000.00 |
| Jun 30, 2011 | 395,000.00 |
| Mar 31, 2011 | 382,000.00 |
| Dec 31, 2010 | 599,000.00 |
| Sep 30, 2010 | 372,000.00 |
| Jun 30, 2010 | 405,000.00 |
| Mar 31, 2010 | 717,000.00 |
| Dec 31, 2009 | 387,000.00 |
| Sep 30, 2009 | 472,000.00 |
| Jun 30, 2009 | 435,000.00 |